A new fibromyalgia drug just reached tens of millions of Medicare members, and patients are already assuming their costs are settled. One document their insurer controls will tell a very different story before open enrollment closes December 7.
New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives) BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second
Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.
Detailed price information for Solventum Corporation (SOLV-N) from The Globe and Mail including charting and trades.
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and
Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.
Mr. Englese’s leadership of Tonix’s commercial organization since 2024 has included the go-to-market strategy and U.S. launch of TONMYA®, with growth across sales, managed care, and patient accessBERKELEY HEIGHTS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the promotion of Thomas Englese to Chief Commercial Officer, effective immediately. Mr
BERKELEY HEIGHTS, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that the management team will participate in a fireside chat and 1x1s at Cantor’s 2026 Global Healthcare Conference, being held September 9-11, 2026, in New York. Cantor’s 2026 Global Healthcare ConferenceFireside ChatPresenter: Seth Lederman, M.D., President and Chief Executive Of
By David Bautz, PhD NASDAQ: TNXP READ THE FULL TNXP RESEARCH REPORT Business Update $11.0 Million in Net Revenue for Tonmya® in 2Q26 Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is continuing the commercial launch of Tonmya® following its approval in August 2025 and commercial launch in November 2025. Sales metrics for the second quarter of 2026 continue to show substantial growth in
This is the newest page. Registered accounts read further back.